TADALAFIL tablet, film coated

Страна: Соединенные Штаты

Язык: английский

Источник: NLM (National Library of Medicine)

Купи это сейчас

Активный ингредиент:

TADALAFIL (UNII: 742SXX0ICT) (TADALAFIL - UNII:742SXX0ICT)

Доступна с:

Proficient Rx LP

Администрация маршрут:

ORAL

Тип рецепта:

PRESCRIPTION DRUG

Терапевтические показания :

Tadalafil Tablets are indicated for the treatment of erectile dysfunction (ED). Tadalafil Tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tadalafil Tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH). If Tadalafil Tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Tadalafil Tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of Tadalafil Tablets beyond 26 weeks is unknown [see Clinical Studies (14.3)] . Administration of Tadalafil Tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. In clinical pharmacology studies, Tadalafil Tablets was shown to potentiate the hypotensive effect of nitrates [see Clinical Pharmacology (12.2)] . Tadalafil Tablets are contraindicated in patients with a known serious hypersensitivity to tadalafil (Tadalafil T

Обзор продуктов:

Tadalafil Tablets USP are supplied as follows: Tadalafil Tablets USP, 5 mg Yellow color, almond shaped film coated tablets debossed with "287" on one side of the tablet and "U" on other side of tablet. Bottle of 10               71205-754-10 Bottle of 20               71205-754-20 Bottle of 30               71205-754-30 Bottle of 60               71205-754-60 Bottle of 90               71205-754-90 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep this and all drugs out of reach of children.

Статус Авторизация:

Abbreviated New Drug Application

Характеристики продукта

                                TADALAFIL- TADALAFIL TABLET, FILM COATED
PROFICIENT RX LP
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
TADALAFIL TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TADALAFIL
TABLETS.
TADALAFIL TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 2003
RECENT MAJOR CHANGES
Warning and Precautions (5.4) 05/2017
INDICATIONS AND USAGE
Tadalafil Tablets are phosphodiesterase 5 (PDE5) inhibitor indicated
for the treatment of:
•
•
•
If Tadalafil Tablets are used with finasteride to initiate BPH
treatment, such use is recommended for up to
26 weeks (1.4).
DOSAGE AND ADMINISTRATION
•
•
•
•
•
•
•
DOSAGE FORMS AND STRENGTHS
Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg (3).
CONTRAINDICATIONS
•
•
•
WARNINGS AND PRECAUTIONS
•
•
•
•
•
•
erectile dysfunction (ED) (1.1)
the signs and symptoms of benign prostatic hyperplasia (BPH) (1.2)
ED and the signs and symptoms of BPH (ED/BPH) (1.3)
_Tadalafil Tablets for use as needed:_
ED: Starting dose: 10 mg as needed prior to sexual activity. Increase
to 20 mg or decrease to 5 mg
based upon efficacy/tolerability. Improves erectile function compared
to placebo up to 36 hours post
dose. Not to be taken more than once per day (2.1).
_Tadalafil Tablets for once daily use:_
ED: 2.5 mg taken once daily, without regard to timing of sexual
activity. May increase to 5 mg based
upon efficacy and tolerability (2.2).
BPH: 5 mg, taken at approximately the same time every day (2.3)
ED and BPH: 5 mg, taken at approximately the same time every day (2.3,
2.4)
Tadalafil Tablets may be taken without regard to food (2.5).
Administration of Tadalafil Tablets to patients using any form of
organic nitrate is contraindicated.
Tadalafil Tablets was shown to potentiate the hypotensive effect of
nitrates (4.1).
History of known serious hypersensitivity reaction to tadalafil
tablets or ADCIRCA (4.2).
®
Administration with guanylate cyclase (GC) stimulators, such as
riociguat (4.3).
Patients should not use Ta
                                
                                Прочитать полный документ
                                
                            

Поиск оповещений, связанных с этим продуктом

Просмотр истории документов